Home > Boards > US Listed > Biotechs > Biohaven Pharmceuticals (BHVN)

Press Release: Biohaven And Royalty Pharma Announce Royalty

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
crudeoil24 Member Profile
Member Level 
Followed By 539
Posts 35,024
Boards Moderated 5
Alias Born 12/12/04
160x600 placeholder
Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in... PR Newswire (US) - 7/15/2019 7:30:00 AM
Biohaven Launches 'Demand More' Campaign At 2019 American Headache Society Annual Scientific Meeting: Highlighting Patient Ne... PR Newswire (US) - 7/11/2019 7:30:00 AM
Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headach... PR Newswire (US) - 7/11/2019 7:30:00 AM
Biohaven's Rimegepant Positive Phase 3 Trial For Acute Treatment Of Migraine Published In The New England Journal of Medicine PR Newswire (US) - 7/10/2019 5:00:00 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 7/10/2019 4:27:44 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2019 5:37:22 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2019 5:36:11 PM
Biohaven Enrolls First Patient in Phase 2 Clinical Trial of Rimegepant, Oral CGRP Receptor Antagonist, for Treatment Refracto... PR Newswire (US) - 7/1/2019 7:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 7:12:12 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 7:10:32 AM
Biohaven To Present 16 Abstracts At 2019 American Headache Society (AHS) Annual Scientific Meeting Highlighting New Data With... PR Newswire (US) - 6/24/2019 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/21/2019 4:06:57 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/20/2019 4:07:22 PM
Biohaven Announces Pricing Of $300 Million Public Offering Of Common Shares PR Newswire (US) - 6/18/2019 10:08:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/18/2019 6:02:55 AM
Biohaven Announces Proposed Public Offering Of Common Shares PR Newswire (US) - 6/17/2019 6:00:00 PM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 6/17/2019 5:15:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/23/2019 6:39:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/23/2019 6:38:26 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/23/2019 6:37:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/23/2019 6:36:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/23/2019 6:35:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/23/2019 6:34:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/22/2019 5:19:50 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/8/2019 5:33:00 PM
crudeoil24 Member Level  Monday, 06/18/18 10:20:32 PM
Re: None
Post # of 12 
Press Release: Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Million
8:06 pm ET June 18, 2018 (Dow Jones) Print
Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Million

- Royalty Pharma acquires approximately 2% royalty rights on global annual net sales of rimegepant and BHV-3500 from Biohaven for $100 million

- Royalty participation rate subject to reduction to 1.50% on global annual net sales exceeding $1.5 billion

- Royalty Pharma agrees to acquire 1,111,111 Biohaven common shares for $50 million, at a price of $45.00 per share, representing an approximately 19% premium over the 15-day volume-weighted average price

PR Newswire

New York Yankees and Duke Basketball
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist